AZ to buy Ardea Biosciences for $1.26 bln

Monday 23 April 2012

AstraZeneca Plc is to acquire Ardea Biosciences Inc of San Diego, California which has a late-stage product for gout. The agreed deal values the US company at $1.26 billion, including the target company’s cash balances. Ardea is listed on Nasdaq.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom